:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Author:	Iskandar Idris
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Diabetes, Obesity and Metabolism Now
Online Access:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1002/doi2.85
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
by: Iskandar Idris
Published: (2024)

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
by: Iskandar Idris
Published: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
by: Iskandar Idris
Published: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
by: Iskandar Idris
Published: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
by: Iskandar Idris
Published: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
by: Iskandar Idris
Published: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
by: Iskandar Idris
Published: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
by: Iskandar Idris
Published: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
by: Iskandar Idris
Published: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
by: Iskandar Idris
Published: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
by: Iskandar Idris
Published: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
by: Iskandar Idris
Published: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
by: Iskandar Idris
Published: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
by: Iskandar Idris
Published: (2024)

Epigenetic changes shown to cause type 2 diabetes
by: Iskandar Idris
Published: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
by: Iskandar Idris
Published: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
by: Iskandar Idris
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Issue Information
Published: (2024)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
by: David C. Klonoff, et al.
Published: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
by: Darren Lau, et al.
Published: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
by: Tae Hyeon Kim, et al.
Published: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
by: Yunwen Xu, et al.
Published: (2025)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
by: Filip K. Knop, et al.
Published: (2024)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
by: Karen L. Jones, et al.
Published: (2024)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
by: Fu‐Shun Yen, et al.
Published: (2025)

Evaluating biased agonism of glucagon‐like peptide‐1 ( GLP ‐1) receptors to improve cellular bioenergetics: A systematic review
by: Sabrina Wong, et al.
Published: (2025)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
by: Lucas Duchemin, et al.
Published: (2025)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
by: Irl B. Hirsch, et al.
Published: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
by: Ruoyang Jiao, et al.
Published: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
by: Jason M. Samuels, et al.
Published: (2024)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
by: Julio Rosenstock, et al.
Published: (2025)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
by: Conner E. Johnson, et al.
Published: (2024)